Weill Cornell Medicine is committed to excellence in patient care, scientific discovery and the education of future physicians in New York City and around the world. Since 1898, our doctors and scientists have been engaged in world-class clinical care and cutting-edge research that connect patients to the latest treatment innovations and prevention strategies. Weill Cornell Medicine's powerful network of collaborators extends to its parent university Cornell University; to Qatar, where Weill Cornell Medicine-Qatar offers a Cornell University medical degree; and to programs in Tanzania, Haiti, Brazil, Austria and Turkey. Weill Cornell Medicine faculty provide exemplary patient care at NewYork-Presbyterian/Weill Cornell Medical Center, NewYork-Presbyterian Westchester Behavioral Health Center, NewYork-Presbyterian Lower Manhattan Hospital, NewYork-Presbyterian Queens and NewYork-Presbyterian Brooklyn Methodist Hospital. Weill Cornell Medicine is also affiliated with Houston Methodist.
Dr. Effie Apostolou, an assistant professor of molecular biology in medicine, has received a 2021 Emerging Leader Award from the Mark Foundation Award for Cancer Research, which recognizes promising early-career projects aimed at addressing unmet needs in cancer research. The Mark Foundation gives the Emerging Leader Awards in an effort to empower scientists who are pursuing innovative, high-risk/high-reward projects that have significant potential to improve outcomes for cancer patients.
Dr. Kai-Ming Fu, an associate professor of neurological surgery, was elected as a new member of the Journal of Neurosurgery: Spine’s Editorial Board. In this role, Dr. Fu will review articles for this journal in the field of spinal neurosurgery.
Dr. Julie Magarian Blander, the Gladys and Roland Harriman Professor of Immunology in Medicine and a member of the Jill Roberts Institute for Research in Inflammatory Bowel Disease, is one of five scientists to receive an inaugural XSeed Award from Deerfield Management. The XSeed Award is a new program designed to support early-stage life science startups; each recipient receives at $100,000 grant. The award will support Dr. Blander’s work with pan-coronavirus vaccines.